chapter 50
DESCRIPTION
Chapter 50. Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels. Prophylaxis of Coronary Heart Disease (CHD). Cholesterol Plasma lipoproteins Role of LDL cholesterol in atherosclerosis - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/1.jpg)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Chapter 50
Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol
and Triglyceride Levels
![Page 2: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/2.jpg)
2Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Prophylaxis of Coronary Heart Disease (CHD)
Cholesterol Plasma lipoproteins Role of LDL cholesterol in atherosclerosis Detection, evaluation, and treatment of high
cholesterol: recommendations from ATP III Drugs and other products used to improve
plasma lipid levels
ATP = Adult Treatment Panel; LDL = low-density lipoprotein.
![Page 3: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/3.jpg)
3Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Cholesterol Component of all cell membranes and
membranes of intracellular organelles Required for synthesis of certain hormones
and bile salts Deposited in stratum corneum of the skin Comes from dietary sources Manufactured by cells, primarily in the liver Increased dietary cholesterol produces only a
small increase in cholesterol in the blood (inhibits endogenous cholesterol production)
![Page 4: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/4.jpg)
4Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Plasma Lipoproteins Structure and function of lipoproteins
Function Basic structure Apolipoproteins
• Recognition sites for cell-surface receptors• Activate enzymes that metabolize lipoproteins• Increase the structural stability of lipoproteins
![Page 5: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/5.jpg)
5Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Plasma Lipoproteins Classes of lipoproteins
Six major classes of plasma lipoproteins Three relevant to coronary atherosclerosis
• Very-low-density lipoproteins (VLDLs) Triglycerides
• Low-density lipoproteins (LDLs) Cholesterol primary core lipid Greatest contributor to coronary heart disease (CHD)
• High-density lipoproteins (HDLs) Cholesterol
![Page 6: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/6.jpg)
6Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Role of LDL Cholesterol in Atherosclerosis
LDLs initiate and fuel development of atherosclerosis
Process begins with transport of LDLs from the arterial lumen into endothelial cells, then into the space underlying the arterial epithelium
![Page 7: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/7.jpg)
7Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Atherogenesis More than just deposit of lipids Now considered primarily a chronic
inflammatory process Infiltration of macrophages, T lymphocytes,
and other inflammatory mediators
![Page 8: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/8.jpg)
8Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Detection, Evaluation, and Treatment of High Cholesterol
Cholesterol screening Every 5 years for adults over the age of 20 years Total cholesterol
• HDL cholesterol Less than 40 mg/dL: low to undesirable
• LDL cholesterol Less than 100 mg/dL: desirable
Triglycerides (TGs)
![Page 9: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/9.jpg)
9Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
CHD Risk Assessment Factors in risk assessment
Identifying CHD risk factors Calculating 10-year CHD risk Identifying CHD risk equivalents
• Diabetes• Atherosclerotic disease other than CHD• Framingham risk score greater than 20%
Identifying an individual’s CHD risk category• Each type of dyslipidemia a patient has contributes
independently to CHD risk
![Page 10: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/10.jpg)
10Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Treatment of High-LDL Cholesterol Therapeutic lifestyle changes (TLCs)
Smoking cessation The TLC diet Exercise
![Page 11: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/11.jpg)
11Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Drug Therapy: Not First-Line Therapy
Drugs should be used only if TLCs fail HMG-CoA reductase inhibitors Bile-acid sequestrants Nicotinic acid (niacin) Fibrates (reduce levels of TGs, not LDLs)
HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A.
![Page 12: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/12.jpg)
12Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Secondary Treatment Targets Metabolic syndrome
High blood glucose High triglycerides High apolipoprotein B Low high-density lipoprotein (HDL) Small LDL particles Prothrombotic state Proinflammatory state Hypertension
High triglycerides Levels above 150 mg/dL
![Page 13: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/13.jpg)
13Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Treatment Goals for Metabolic Syndrome
Reduce the risk for atherosclerotic disease Reduce the risk for type 2 diabetes Increase physical activity
![Page 14: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/14.jpg)
14Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Drugs and Other Products to Alter Plasma Lipid Levels
High LDL: contributes most to cardiovascular disease
Also consider High total cholesterol Low HDL cholesterol High triglycerides
Drugs can improve lipid profiles, but not all improve clinical outcomes
![Page 15: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/15.jpg)
15Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
HMG-CoA Reductase Inhibitors (Statins)
Most effective drugs for lowering LDL Reduction of LDL cholesterol Elevation of HDL cholesterol Reduction of triglyceride levels Nonlipid beneficial cardiovascular actions
Promote plaque stability Reduce the risk for cardiovascular (CV) events Increased bone formation
![Page 16: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/16.jpg)
16Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
HMG-CoA Reductase Inhibitors (Statins)
Mechanism of cholesterol reduction Clinical trials Therapeutic uses
Hypercholesterolemia Primary and secondary prevention of CV events Post-MI therapy Diabetes Potential uses
![Page 17: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/17.jpg)
17Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
HMG-CoA Reductase Inhibitors (Statins)
Adverse effects Common
• Headache• Rash• GI disturbances
Rare • Myopathy/rhabdomyolysis• Hepatotoxicity
![Page 18: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/18.jpg)
18Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
HMG-CoA Reductase Inhibitor (Statins)
Drug interactions Most other lipid-lowering drugs (except bile acid
sequestrants) Drugs that inhibit CYP3A4 Use in pregnancy
Dosing should be once daily in the evening Endogenous cholesterol synthesis increases
during the night Statins have greatest impact when given in
the evening
![Page 19: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/19.jpg)
19Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Nicotinic Acid (Niacin) Reduces LDL and TG levels Increases HDL levels more effectively than
any other drug Effect on plasma lipoproteins
Lowering TG levels Raising HDL cholesterol
![Page 20: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/20.jpg)
20Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Nicotinic Acid (Niacin) Adverse effects
Skin (flushing, itching)• Intense flushing initially; can pretreat with aspirin• Decreased with SR version of niacin
Gastrointestinal Hepatotoxicity Hyperglycemia Gouty arthritis Can raise blood levels of uric acid
![Page 21: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/21.jpg)
21Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Bile-Acid Sequestrants Previously were first-line drugs Now primarily used as adjuncts to statins Cholestyramine Colestipol Colesevelam
Newest and better-tolerated drug Does not decrease uptake of fat-soluble vitamins
(as other bile sequestrants do) Does not significantly reduce the absorption of
statins, warfarin, digoxin, and most other drugs studied
![Page 22: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/22.jpg)
22Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Bile-Acid Sequestrants
Colesevelam (cont’d) Reduction in LDL cholesterol Increased VLDL levels in some patients Mechanism of action
• Increases LDL receptors on hepatocytes• Prevents reabsorption of bile acids
Therapeutic use• Reduces LDL cholesterol (in conjunction with modified
diet and exercise) Adverse effects
• Constipation
![Page 23: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/23.jpg)
23Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Ezetimibe Mechanism of action and impact on plasma
lipids Inhibits cholesterol absorption
Therapeutic use Reduces total cholesterol, LDL cholesterol, and
apolipoprotein B Approved for monotherapy and combined use with
statins
![Page 24: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/24.jpg)
24Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Ezetimibe Adverse effects
Myopathy Rhabdomyolysis Hepatitis Pancreatitis Thrombocytopenia
Drug interactions Statins Fibrates Bile-acid sequestrants Cyclosporine
![Page 25: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/25.jpg)
25Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Fibric Acid Derivatives (Fibrates) Most effective drugs available for lowering TG levels Can raise HDL cholesterol Little or no effect on LDL cholesterol Can increase the risk for bleeding in patients on
warfarin Can increase the risk for rhabdomyolysis in patients
taking statins Three drugs in the United States
Gemfibrozil (Lopid) Fenofibrate (Tricor, others) Fenofibric acid (TriLipix)
![Page 26: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/26.jpg)
26Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Gemfibrozil Effects on plasma lipoproteins
Decreases plasma TG content Lowers VLDL levels Can raise HDL cholesterol
Mechanism Appears to interact with a specific receptor
subtype (PPAR alpha) Drug interactions
Displaces warfarin from plasma albumin Measure INR frequently
![Page 27: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/27.jpg)
27Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Gemfibrozil Therapeutic uses
Reduces high levels of plasma triglycerides (VLDLs) Treatment reserved for patients who have not responded to
diet modification Less effective than statins in reducing LDL Can raise HDL (not approved for this use)
Adverse effects Rashes Gastrointestinal disturbances Gallstones Myopathy Liver injury (hepatotoxic)
![Page 28: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/28.jpg)
28Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Other Products Used to Alter Plasma Lipid Levels
Fenofibrate Fenofibric acid Drug combinations
Niacin/lovastatin Simvastatin/niacin, simvastatin/ezetimibe Pravastatin/aspirin Atorvastatin/amlodipine
![Page 29: Chapter 50](https://reader036.vdocument.in/reader036/viewer/2022062410/5681663f550346895dd9abe0/html5/thumbnails/29.jpg)
29Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Other Products Used to Alter Plasma Lipid Levels
Lovaza Fish oil Plant stanol and sterol esters Estrogen Cholestin